The societal impact of early intensified treatment in patients with type 2 diabetes mellitus

被引:7
|
作者
Tsotra, Foteini [1 ]
Kappel, Mathias [2 ]
Peristeris, Platon [1 ]
Bader, Giovanni [3 ]
Levi, Eva [1 ]
Lister, Nicola [4 ]
Malhotra, Ankur [5 ]
Ostwald, Dennis A. [2 ,6 ]
机构
[1] WifOR Inst, Athens, Greece
[2] WifOR Inst, Darmstadt, Germany
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Global Hlth & Sustainabil, Johannesburg, South Africa
[5] Novartis India Ltd, Mumbai, Maharashtra, India
[6] Steinbeis Univ, Grad Sch, SIBE, Fac Leadership & Management, Berlin, Germany
关键词
antidiabetes treatment; diabetes complications; early intensified treatment; metformin monotherapy; productivity costs; societal impact; type 2 diabetes mellitus; CARDIOVASCULAR OUTCOMES; GLUCOSE CONTROL; WORK; RETURN; PREVALENCE; INSULIN; RISK;
D O I
10.2217/cer-2022-0110
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Aim: The current study estimates the societal impact of early intensified treatment compared with initial monotherapy with subsequent treatment intensification in newly diagnosed adults with type 2 diabetes mellitus in Mexico. Methods: An individual patient-level simulation and a static cohort model were employed to simulate the treatment pathway and the probability of experiencing complications of diabetes. The avoided number of events was translated into avoided productivity losses, which were monetized using wages. Results: Patients on early intensified treatment experienced approximately 13,000 fewer complication events over 10 years. This was translated into a societal impact of $54 million (USD). Conclusion: Early treatment intensification is likely to be of particular benefit to health outcomes and productivity losses.
引用
收藏
页码:1185 / 1199
页数:15
相关论文
共 50 条
  • [21] Early insulin therapy in patients with type 2 diabetes mellitus
    Mashitisho, M. L. I.
    Mashitisho, B. G.
    JOURNAL OF ENDOCRINOLOGY METABOLISM AND DIABETES OF SOUTH AFRICA, 2016, 21 (01) : 13 - 15
  • [22] Deintensification of Diabetes Treatment in Elderly Patients with Type 2 Diabetes Mellitus
    Pirela, Daniela V.
    Garg, Rajesh
    DIABETES, 2019, 68
  • [23] Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus
    Vieira, Ines Henriques
    Carvalho, Tania Santos
    Saraiva, Joana
    Gomes, Leonor
    Paiva, Isabel
    BIOMEDICINES, 2024, 12 (05)
  • [24] The Impact of Planned Visits on Patients with Type 2 Diabetes Mellitus
    Nuovo, Jim
    CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2009, 2 : 7 - 14
  • [25] Insulinglulisine and aspart insulin are equipotent in intensified insulin therapy of patients with type 2 diabetes mellitus
    Jungmann, E.
    Bolle, J.
    Schmitz, C.
    Snelting, U.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 : 67 - 68
  • [26] Treatment Satisfaction in Patients with Diabetes Mellitus Type 1 Treated with Intensified Insulin Therapy with Insulin Analogues
    Radenkovic, Sasa
    Golubovic, Milena Velojic
    Radojkovic, Danijela
    Ciric, Vojislav
    Kocic, Radivoj
    ACTA FACULTATIS MEDICAE NAISSENSIS, 2021, 38 (03) : 240 - 246
  • [27] Macrovascular disease in type 1 diabetes mellitus: Effects of intensified insulin treatment
    Diem, P
    Steffes, MW
    Egger, M
    DIABETES, 2001, 50 : A152 - A152
  • [28] Erectile Dysfunction in Type-2 Diabetes Mellitus Patients: Predictors of Early Detection and Treatment
    Fan, Junhong
    Peng, Tianwen
    Hui, Jialiang
    Ding, Wei
    He, Binglin
    Zhang, Haibo
    Wei, Anyang
    UROLOGIA INTERNATIONALIS, 2021, 105 (11-12) : 986 - 992
  • [29] The impact of early basal insulin treatment on inflammation and endothelial activation/damage related biomarkers in patients with type 2 diabetes mellitus
    Kesikli, S. A.
    Unluturk, U.
    Gunaydin, G.
    Ates, C.
    Guc, D.
    Uysal, A. R.
    Emral, R.
    IMMUNOLOGY, 2012, 137 : 46 - 47
  • [30] Early Discontinuation and Restart of Insulin in the Treatment of Type 2 Diabetes Mellitus
    Haya Ascher-Svanum
    Maureen J. Lage
    Magaly Perez-Nieves
    Matthew D. Reaney
    Joanne Lorraine
    Angel Rodriguez
    Michael Treglia
    Diabetes Therapy, 2014, 5 : 225 - 242